Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 177

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients

Open access
Huls, Gerwin, Chitu, Dana A., Havelange, Violaine, Jongen-Lavrencic, Mojca, van de Loosdrecht, Arjan A., Biemond, Bart J., Sinnige, Harm, Hodossy, Beata, Graux, Carlos, Kooy, Rien van Marwijk, de Weerdt, Okke, Breems, Dimitri, Klein, Saskia, Kuball, Jürgen, Deeren, Dries, Terpstra, Wim, Vekemans, Marie-Christiane, Ossenkoppele, Gert J., Vellenga, Edo, Löwenberg, Bob, the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) · 2019 · Blood

Abstract

The prevention of relapse is the major therapeutic challenge in older patients with acute myeloid leukemia (AML) who have obtained a complete remission (CR) on intensive chemotherapy. In this randomized phase 3 study (HOVON97) in older patients (≥60 years) with AML or myelodysplastic syndrome with refractory anemia with excess of blasts, in CR/CR with incomplete hematologic recovery (CRi) after at least 2 cycles of intensive chemotherapy, we assessed the value of azacitidine as postremission therapy with respect to disease-free survival (DFS; primary end point) and overall survival (OS; secondary end point). In total, 116 eligible patients were randomly (1:1) assigned to either observation (N = 60) or azacitidine maintenance (N = 56; 50 mg/m2, subcutaneously, days 1-5, every 4 weeks) until relapse, for a maximum of 12 cycles. Fifty-five patients received at least 1 cycle of azacitidine, 46 at least 4 cycles, and 35 at least 12 cycles. The maintenance treatment with azacitidine was feasible. DFS was significantly better for the azacitidine treatment group (logrank; P = .04), as well as after adjustment for poor-risk cytogenetic abnormalities at diagnosis and platelet count at randomization (as surrogate for CR vs CRi; Cox regression; hazard ratio, 0.62; 95% confidence interval, 0.41-0.95; P = .026). The 12-month DFS was estimated at 64% for the azacitidine group and 42% for the control group. OS did not differ between treatment groups, with and without censoring for allogeneic hematopoietic cell transplantation. Rescue treatment was used more often in the observation group (n = 32) than in the azacitidine maintenance group (n = 9). We conclude that azacitidine maintenance after CR/CRi after intensive chemotherapy is feasible and significantly improves DFS. The study is registered with The Netherlands Trial Registry (NTR1810) and EudraCT (2008-001290-15).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2018-10-879866

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 177

Metadata

Authors
Huls, G., Chitu, D. A., Havelange, V., Jongen-Lavrencic, M., van de Loosdrecht, A. A., Biemond, B. J., Sinnige, H., Hodossy, B., Graux, C., Kooy, R. V. M., de Weerdt, O., Breems, D., Klein, S., Kuball, J., Deeren, D., Terpstra, W., Vekemans, M.-C., Ossenkoppele, G. J., Vellenga, E., Löwenberg, B., & the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON)
Venue
Blood
Published
2019-03-28
Volume
133
Issue
13
Pages
1457-1464
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2909763242
Cited by
177
References
3
FWCI
17.53
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients. https://app.cochat.ai/papers/10.1182/blood-2018-10-879866
The paper
Huls, G., Chitu, D. A., Havelange, V., Jongen-Lavrencic, M., van de Loosdrecht, A. A., Biemond, B. J., Sinnige, H., Hodossy, B., Graux, C., Kooy, R. V. M., de Weerdt, O., Breems, D., Klein, S., Kuball, J., Deeren, D., Terpstra, W., Vekemans, M.-C., Ossenkoppele, G. J., Vellenga, E., . . . the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON). (2019). Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients. Blood. https://doi.org/10.1182/blood-2018-10-879866

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.